CA2708229A1 - Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor - Google Patents
Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor Download PDFInfo
- Publication number
- CA2708229A1 CA2708229A1 CA2708229A CA2708229A CA2708229A1 CA 2708229 A1 CA2708229 A1 CA 2708229A1 CA 2708229 A CA2708229 A CA 2708229A CA 2708229 A CA2708229 A CA 2708229A CA 2708229 A1 CA2708229 A1 CA 2708229A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- sorafenib
- group
- melanoma
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 41
- 108010046075 Thymosin Proteins 0.000 title claims abstract description 32
- 229940043355 kinase inhibitor Drugs 0.000 title claims abstract description 23
- 239000003757 phosphotransferase inhibitor Substances 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title description 35
- 102000007501 Thymosin Human genes 0.000 title description 3
- 238000011269 treatment regimen Methods 0.000 claims abstract description 26
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 230000009401 metastasis Effects 0.000 claims abstract description 5
- 238000002648 combination therapy Methods 0.000 claims abstract description 3
- 108010078233 Thymalfasin Proteins 0.000 claims description 134
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 134
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 133
- 229960004231 thymalfasin Drugs 0.000 claims description 132
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 109
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 108
- 229960003787 sorafenib Drugs 0.000 claims description 108
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 26
- 239000002295 alkylating antineoplastic agent Substances 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 description 61
- 239000003981 vehicle Substances 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 33
- 230000037396 body weight Effects 0.000 description 33
- 239000003814 drug Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 208000001382 Experimental Melanoma Diseases 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000013641 Cerebrofacial arteriovenous metameric syndrome Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 108700016958 thymosin fraction 5 Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1347607P | 2007-12-13 | 2007-12-13 | |
| US61/013,476 | 2007-12-13 | ||
| PCT/US2008/086545 WO2009076587A1 (en) | 2007-12-13 | 2008-12-12 | Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2708229A1 true CA2708229A1 (en) | 2009-06-18 |
Family
ID=40755899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2708229A Abandoned CA2708229A1 (en) | 2007-12-13 | 2008-12-12 | Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100267637A1 (enExample) |
| EP (1) | EP2240194A4 (enExample) |
| JP (1) | JP2011506473A (enExample) |
| CN (1) | CN101945664A (enExample) |
| AR (1) | AR069769A1 (enExample) |
| AU (1) | AU2008335025A1 (enExample) |
| CA (1) | CA2708229A1 (enExample) |
| WO (1) | WO2009076587A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943101A1 (en) * | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| EP2633866A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
| US20070292392A1 (en) * | 2006-06-15 | 2007-12-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
-
2008
- 2008-12-12 CN CN2008801268138A patent/CN101945664A/zh active Pending
- 2008-12-12 AU AU2008335025A patent/AU2008335025A1/en not_active Abandoned
- 2008-12-12 JP JP2010538181A patent/JP2011506473A/ja active Pending
- 2008-12-12 US US12/747,438 patent/US20100267637A1/en not_active Abandoned
- 2008-12-12 WO PCT/US2008/086545 patent/WO2009076587A1/en not_active Ceased
- 2008-12-12 EP EP08858909A patent/EP2240194A4/en not_active Withdrawn
- 2008-12-12 CA CA2708229A patent/CA2708229A1/en not_active Abandoned
- 2008-12-15 AR ARP080105451A patent/AR069769A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011506473A (ja) | 2011-03-03 |
| AR069769A1 (es) | 2010-02-17 |
| US20100267637A1 (en) | 2010-10-21 |
| EP2240194A4 (en) | 2011-12-21 |
| CN101945664A (zh) | 2011-01-12 |
| AU2008335025A1 (en) | 2009-06-18 |
| EP2240194A1 (en) | 2010-10-20 |
| WO2009076587A1 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7133070B2 (ja) | ベンダムスチンの製剤 | |
| HU220599B1 (hu) | Eljárás komplementer inhibitorokat tartalmazó, nekrotizáló véredénylézió kezelésére alkalmas gyógyászati készítmények előállítására | |
| US20110224150A1 (en) | Methods for effecting regression of tumor mass and size in a metastasized tumor | |
| US20100317583A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) | |
| AU2002310788B2 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| CA2709027A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| EP0484340B1 (en) | Treatment to reduce edema for brain and musculature injuries | |
| Wilson et al. | Antibiotic prophylaxis in cardiac surgery: a prospective comparison of two dosage regimens of teicoplanin with a combination of flucloxacillin and tobramycin | |
| Stewart | Pegvisomant: an advance in clinical efficacy in acromegaly | |
| CN101972471B (zh) | 乌司他丁用于制备治疗自身免疫性脑脊髓炎药物的用途及其药物组合物 | |
| JP2002534477A (ja) | メラガトランの新規使用 | |
| CA2708229A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor | |
| ES2791301T3 (es) | Combinación de canrenoato y exenatida | |
| EP2106791A1 (en) | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | |
| KR102606504B1 (ko) | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 | |
| Katsumata et al. | Neuroprotective effect of NS-7, a novel Na+ and Ca2+ channel blocker, in a focal ischemic model in the rat | |
| Fang et al. | Modern Treatment of severe burns | |
| Von Degerfeld | Personal experiences in the use of Zoletil® for anaesthesia of the red-necked wallaby (Macropus rufogriseus) | |
| RU2839802C1 (ru) | Способ реабилитации больных с синдромом хронической усталости после перенесенной коронавирусной инфекции на основе пептидных биорегуляторов с помощью спрея сублингвального введения | |
| US20130079416A1 (en) | Homeopathic medicament comprising phenacetin for the treatment of cancer | |
| Purwanthi et al. | Administration of botulinum toxin a and vascular endhotelial growth factor reduce norepinephrine levels and increase viability of modified mcfarlane flap in wistar rat | |
| US11058707B2 (en) | Methods for treating ischemic heart disease by targeting TRPV4 | |
| Javitt et al. | Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide | |
| KR20250098482A (ko) | Hb-egf 단백질 또는 이를 코딩하는 폴리뉴클레오타이드를 유효성분으로 포함하는 말초신경병증 예방 또는 치료용 약학 조성물 | |
| TR2024021224A2 (tr) | Pi̇gment epi̇teli̇nden türeti̇len faktör (pedf)?ni̇n osteoporoz tedavi̇si̇nde kullanilmasi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20141212 |